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ADVANCES IN NONNUCLEAR IMAGING TECHNOLOGIES
Myocardial perfusion imaging by cardiac
magnetic resonance
Juerg Schwitter, MDa,b,c
Cardiovascular magnetic resonance (CMR) has been shown to provide high quality data on
cardiac and valvular function, perfusion, viability, blood flow, and potentially, on cardiac
metabolism as well. Several of these CMR applications (eg, function and viability assessment)
matured during the past years and are now established components of a cardiac workup.
Perfusion-CMR is close to this status and is already a major contributor to cardiac examinations
in a growing number of expert centers. Large multicenter perfusion-CMR trials comparing the
diagnostic performance of CMR with other techniques were recently reported yielding areas
under the receiver-operator-characteristics curve as a high as 0.85 for coronary artery disease
detection (MR-IMPACT). Anticipating a growing role for perfusion-CMR in cardiology in the
near future, this article discusses the principles of perfusion-CMR and its integration into the
workup of patient with coronary artery disease (CAD). In addition to a functional study, this
integration is mainly composed of a perfusion-CMR part, followed by a viability assessment by
late enhancement CMR techniques. The principal characteristics of these CMR techniques are
compared with those of single photon emission computed tomography (SPECT) and positron
emission tomography (PET). After introduction into principles and techniques of perfusion-
CMR, some open questions in perfusion-CMR and challenges for the future are addressed.
Finally, newer CMR applications are shortly mentioned utilizing hyperpolarized carbon-13
compounds in experimental models for quantification of myocardial perfusion and for real-time
assessment of metabolic pathways in postischemic myocardium. (J Nucl Cardiol 2006;13:
841-54.)
For more than 100 years, cardiovascular disease has
been the number one cause of death in the United States,
and coronary artery disease (CAD) is by far the most
important contributor to this disease burden. Large stud-
ies using scintigraphic techniques are the major source of
evidence demonstrating the importance of the severity
and extent of ischemia for the patients’ prognosis.1-3 In
thousands of patients with risk factors but normal scin-
tigrams, the prognosis is excellent,1,2 which is in line
with invasive studies, which showed an event rate of
1.1%/y in the mid 1980s for patients with angiograms
with stenoses of 50% or less in diameter.4 Taking
advantage of the prognostic information provided by the
scintigraphic examinations, it was shown that costs for
patient management could be reduced by 30% to 40%
without any compromise in the quality of outcome when
a noninvasive single photon emission computed tomog-
raphy (SPECT) approach was applied first in comparison
to a direct invasive approach.5 These considerations
underline the paramount importance of perfusion assess-
ment for patient workup and decision making.
PRINCIPLES OF ISCHEMIA AND VIABILITY
IMAGING: COMPARISON OF CARDIAC MAGNETIC
RESONANCE WITH SCINTIGRAPHIC TECHNIQUES
For the assessment of myocardial perfusion, perfu-
sion–cardiac magnetic resonance (CMR) typically exploits
the first-pass kinetics of conventional T1-enhancing extra-
cellular gadolinium chelates. This concept has been ap-
plied first in animals6-8 and consequently in human
beings.9,10 The magnetic resonance (MR) contrast me-
dium (CM) enters the microvasculature and also starts to
diffuse within the interstitial space during the first
pass.11,12 As a result, the signal intensity of the myocar-
dium increases, the rate of which is linked to the
perfusion status of the tissue. Accordingly, normally
perfused myocardium demonstrates a fast signal increase
per unit time in the vasodilated state, whereas signal
increase is delayed in myocardium supplied by a criti-
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cally stenosed coronary artery. Because the first pass
lasts only a few seconds, the data acquisition can be
completed within a breath-hold, which efficiently elimi-
nates respiratory motion. In addition, the MR data
collection is electrocardiography (ECG)–triggered,
which eliminates cardiac motion. Together, breath-hold-
ing and ECG-triggering preserve the nominally high
spatial resolution for perfusion data on the order of 1.5 to
2.5 mm  1.5 to 2.5 mm. This excellent spatial resolu-
tion allows for discrimination of perfusion deficits that
are limited to the vulnerable subendocardial layer of
the left ventricular myocardium.10,13,14 For compari-
son, in SPECT imaging technetium 99m–labeled tracers
generally accumulate in viable myocytes in relation to
tissue perfusion, demonstrating normally perfused myo-
cardium as hot tissue, whereas hypoperfused areas ap-
pear as cold spots similar to the perfusion-CMR situation
(Figure 1). Once areas with reduced perfusion during
hyperemia are recognized, it is important to discriminate
hypoperfused scar tissue from hypoperfused but viable
myocardium (ie, ischemic tissue). For this purpose, both
CMR and SPECT imaging are based on the redistribu-
tion of CM. For CMR, the technique is called late
enhancement (LE) or delayed enhancement (DE), and it
measures the accumulation of CM within the expanded
interstitial space present in scar tissue. SPECT measures
the redistribution of CM (ie, radiolabeled tracer) into
viable myocytes, delineating scar as a cold spot after
rest-injection or rest-reinjection (Figure 1). For CMR,
the conventional gadolinium chelates are excluded from
intact cell membranes and therefore are restricted to a
small distribution volume of approximately 20% in
viable myocardium. In scar tissue and particularly in
acute myocyte necrosis the distribution volume may
increase up to 100%.15,16 Consequently, with LE- or
DE-CMR imaging, scar and acute myocardial necrosis
appear as bright tissue. Thus both CMR and SPECT
imaging assess perfusion during a vasodilated state (ie,
stress imaging or a CMR stress-only protocol) and
compare hyperemic perfusion data with a reference (ie, a
normal database or a normal segment of the studied
heart). For viability imaging, both CMR and SPECT
detect scar and necrosis by means of redistribution
imaging after a resting (re)injection.
An alternative to the CMR stress-only protocol has
been proposed for ischemia detection, in which CMR
perfusion data acquired during vasodilation are divided
by resting perfusion data (stress-rest protocol) to derive
coronary flow reserve (CFR).17 This strategy is the
analog for the positron emission tomography (PET)
perfusion approach, in which compromised CFR is
indicative of the presence of CAD.10,18-22 For viability
imaging, PET is not relying on redistribution of a flow
tracer but directly probes preserved cellular metabolism,
for example, by the membrane transport and trapping of
fluorine 18 fluorodeoxyglucose (FDG). Here, the CFR
concept of CMR (ie, stress-rest protocol) requires addi-
tional redistribution imaging—that is, an LE- or DE-CMR
imaging approach for viability assessment (Figure 1).
A CMR and PET example is given in Figure 2. The
analog for viability FDG-PET imaging is then the com-
bination of CMR with hyperpolarized carbon 13 com-
pounds, which is currently applied successfully in animal
studies.23 With a variety of hyperpolarized C-13 com-
pounds, it will be possible to visualize and quantify the
crucial metabolic pathways in the myocytes and thereby
to characterize their metabolic state.
For the assessment of myocardial perfusion (ie, the
detection of reduced hyperemic perfusion), 2 CMR
approaches are currently under consideration, involving
either assessment of hyperemic perfusion only (stress-
only protocol) or assessment of CFR (stress-rest proto-
col). Future studies are warranted to identify the ideal
approach. Whereas the first approach (ie, stress-only
protocol) requires a normal database to provide threshold
values for the hyperemic flow state, the CFR approach
incorporates measurements of resting flow. Division of
hyperemic flow by resting flow may become problem-
atic, considering that factors such as heart rate, contrac-
tility, and loading conditions influence resting flow but
are difficult to control during a clinical routine examina-
tion.24 Furthermore, matching myocardial regions for
both resting and hyperemic conditions may be difficult
(because the geometry of the heart changes with chang-
ing heart rate, loading, and so on). Most importantly, the
CMR technique must guarantee a linear relationship
between MR-derived perfusion parameters and true per-
fusion over a wide range of conditions (ie, resting and
hyperemic conditions) to obtain accurate CFR results.
Recently, the stress-rest protocol was advocated to help
discriminate artifacts from true perfusion deficits,25 in
that a signal loss being present on both the rest and stress
perfusion studies but not matching a bright “scar” signal
on LE-CMR would indicate the presence of an artifact.
Although such a decision algorithm could be of help in
low-quality examinations to detect artifacts, it is clearly
suggested to improve the MR pulse sequences to reduce
the frequency of artifacts (as also discussed in the
sections entitled “Acquisition of perfusion data by
CMR” and “Contrast media: Types and doses”). An
example of a perfusion and anatomic abnormality in a
patient with atypical chest pain is given in Figure 3.
ACQUISITION OF PERFUSION DATA BY CMR
Magnetization Preparation
Today, most experience exists for the first-pass
approach involving T1-enhancing MR CM. To increase
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Figure 1. Mechanisms for CMR imaging considering a T1-weighted sequence and a conventional
T1-enhancing CM (MR CM) (top row), scintigraphy (SPECT) (middle row), and PET (bottom row)
for the assessment of myocardial perfusion (middle column) and viability (right column). In the left
column, the 4 main conditions of myocardium are depicted: normal (nonischemic) myocardium,
ischemic myocardium, and acute necrotic tissue representing acute myocardial infarction (AMI), as
well as its sequelae, chronic scar tissue. In these schematics the extracellular compartment contains
intravascular (plasma) and extravascular space (ie, interstitium). In chronic scar tissue the small
fibrocytes are embedded within a large extracellular (ie, interstitial) space. The middle column
demonstrates perfusion assessment. For CMR, in normally perfused myocardium the MR CM
distributes within the extracellular compartment during the first pass, causing signal increase. In
hypoperfused myocardium first-pass wash-in kinetics is delayed and signal increase is slow. For
SPECT (middle row), radiolabeled tracer is trapped within viable myocytes in relation to perfusion;
that is, less tracer accumulation occurs in hypoperfused, ischemic tissue, which appears as a cold
spot. In scar and acute necrotic tissue slow wash-in occurs for both radiotracer and MR CM. For
viability assessment (right column), equilibrium distribution is required for both radiotracer and MR
CM. For MR CM, the distribution volume in AMI and scar tissue is large, with a consequent high
concentration of MR CM in both necrotic and scar tissue appearing bright on LE-CMR imaging
(with inversion time nulling viable myocardium). For SPECT, radiotracer is not accumulated either
in AMI or in fibrocytes, and necrosis and scar appear as a cold spot (ie, fixed defect), whereas the
radiotracer accumulates in viable myocytes of ischemic myocardium, yielding a hot spot (ie,
reversible defect). Of importance, the combination of perfusion-CMR and LE-CMR is the analog of
the classical combined SPECT stress and redistribution resting study. The combined perfusion-
viability CMR study is short, because equilibrium distribution is typically achieved within 15 to 20
minutes. In addition, data acquisition by CMR lasts only a few seconds, allowing breath-holding and
ECG-triggering to be used, which preserves a high spatial resolution of both the perfusion
and viability CMR data. For ischemia assessment by PET, typically, a stress (ie, hyperemic) study
and a resting perfusion study are performed by use of N-13 ammonia or oxygen 15 water flow
tracers, and a reduced perfusion reserve is indicative of a compromised blood supply to a given
myocardial territory. This PET approach is adopted by the first-pass stress and rest perfusion-CMR
approach (stress-rest protocol), yielding a perfusion reserve index. The viability assessment then
requires an additional LE-CMR study, which corresponds to the FDG-PET study. Whereas
FDG-PET probes glucose transport, hyperpolarized C-13 CM with CMR allows for monitoring (eg,
Krebs cycle) in near real time.
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the sensitivity of the pulse sequence for changing
CM concentrations, the magnetization may be prepared
before data readout occurs. In the past an inversion
recovery preparation was most often used,6,8,9,17,26-28
because it provides a large dynamic range of signal
response, theoretically from negative to positive longi-
tudinal magnetizations Mz to Mz. However, in prac-
tice the delay time from preparation to readout was
selected to obtain near-zero magnetization before the
start of readout, which required 300 to 400 milliseconds
of waiting time, thus precluding true multislice imaging.
Therefore the currently accepted preparation is a satura-
tion recovery approach, which renders the signal re-
sponse independent of heart rate variations and further
shortens the waiting time down to 100 to 200 millisec-
onds.10,29-35 It should be noted at this point that the
selection of the optimum delay time should not only
optimize signal response for the expected changes in
CM concentration during the first pass but also locate
the window for data readout into phases of the cardiac
Figure 2. An example of a CMR and PET study in a 55-year-old man with atypical chest pain.
First-pass perfusion-CMR (A) demonstrates a large subendocardial perfusion deficit (dark area) in
the anterolateral, septal, and inferior wall of the left ventricle, whereas the subepicardial layer and
lateral wall are perfused normally (bright area). Correspondingly, on the N-13 ammonia PET study
(B), only the lateral wall is normally perfused during hyperemia. C, A polar map is reconstructed
from the perfusion-CMR study, where the normal ranges for upslope values in each segment were
derived from receiver operating characteristic curves (for the detection of50% diameter stenoses).
D, LE-CMR study in this patient, visualizing subendocardial scar tissue (bright) in the anterior and
anteroseptal region, with a thrombus (black) attached to the infarcted territory. E, F-18 FDG–PET
demonstrates severely reduced FDG uptake (ie, reduced viability) in the region of subendocardial
scar. F, A polar map is reconstructed from the LE-CMR study, visualizing the distribution of
subendocardial scar tissue (50% transmurality) in the left ventricular myocardium. These CMR
and PET findings are in good agreement with the invasive x-ray coronary angiography, demon-
strating an occlusion (and collateral channels) of the proximal and mid left anterior descending
coronary artery (LAD) (arrows in G), leading to a subendocardial infarction in the core of the supply
territory of the LAD (D-F) and compromised hyperperfusion during vasodilation in the border zones
(A-C). The inferior and inferoseptal region of compromised hyperperfusion during vasodilation in
A through C is caused by an additional stenosis at the crux of the right coronary artery (RCA) (arrow
in H). LCX, Left circumflex artery.
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cycle where motion is minimal. Data acquisition in late
systole and mid diastole is typically achieved with a
delay time of 100 to 150 milliseconds.10,29
Data Readout Strategies
Because the prognosis of patients is dependent on the
extent of perfusion deficits, the aim of perfusion-CMR is to
cover the relevant portions of the myocardium. In addition, to
obtain signal intensity–time curves from which perfusion
parameters can be derived, it is suggested to achieve a temporal
resolution of 1 stack covering the left ventricular myocardium
being acquired every 1 to 2 RR intervals. These conditions
demonstrate that very fast data acquisition is crucial for
perfusion imaging. One such fast approach is called echo-
planar imaging (EPI), which describes the acquisition of a full
k-space (required to reconstruct 1 single image) after a single
radiofrequency excitation. In contrast, with a conventional fast
gradient echo approach, 1 radiofrequency excitation is required
for every line in k-space (eg, 256 excitations for a matrix of
256 256). Single shot EPI is very fast, but its relatively long
echo time renders the sequence prone to susceptibility arti-
facts.36 Therefore a hybrid-EPI approach appears to be ideal, in
which 4 to 8 k-lines per radiofrequency excitation are
acquired.10,32-34,37 Steady-state free precession pulse se-
quences preserve magnetization and are particularly
promising with respect to a high signal-to-noise ratio
(SNR) but may suffer from other disadvantages because
of the relatively long acquisition windows, as shown in
Figure 4. Alternatively, parallel imaging techniques can
be combined with perfusion imaging.38 These techniques
acquire data from folded fields of view and resolve
wraparound artifacts by taking into account the different
spatial sensitivities of various coil elements.39 In general,
parallel imaging techniques trade the SNR for speed of
acquisition. However, meticulous optimization of other
imaging parameters can minimize this disadvantage.38
These parallel imaging approaches can be combined with
Figure 3. Example of images in a 47-year-old man with rare atypical chest pain and a positive
treadmill test. The first-pass perfusion-CMR study shows an extensive area of compromised
hyperperfusion during hyperemia in the subendocardial layer of the anterolateral wall and the
interventricular septum as marked by the arrowheads (A-C). In D through F, the time series during
the first pass of the CM in the most basal slice is shown. It demonstrates CM first appearing in the
right atrium and the right ventricular outflow tract but also in the coronary sinus (D), whereas the
left ventricular cavity is not contrasted. CM then enters the left ventricular cavity (E) and finally
washes out of the coronary sinus and right atrium (F). This sequence of CM arrival is explained by
the rare case of an agenesis of the superior vena cava (G). The venous return of the upper body
drains into a persistent left superior vena cava, which finally enters the coronary sinus. This example
demonstrates the ability of CMR to provide important anatomic information in addition to
high-resolution perfusion information.
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techniques that exploit spatiotemporal correlations in
k-t–space, which results in even higher acceleration
factors. Techniques such as k-t BLAST (Broad-use
Linear Acquisition Speed-up Technique) and k-t SENSE
(SENSitivity Encoding)40 achieve high acceleration fac-
tors but might demonstrate higher susceptibility to mo-
tion and could smooth temporal information. Thus future
studies will be needed to assess the potential of these
newer techniques.
Besides selection of the optimal pulse sequence for
fast perfusion data acquisition, the imaging parameters
for a given pulse sequence are crucial with respect to the
SNR and contrast-to-noise ratio (CNR), spatial and
temporal resolution, and cardiac coverage. It could be
demonstrated that for a given hybrid-EPI pulse sequence,
the signal change during the first pass can range from
70% up to 280% of baseline signal, which translated into
an acceptable diagnostic performance for the optimized
imaging parameters, yielding a sensitivity and specificity
of 82% and 73%, respectively, for detection of stenoses
of 50% or greater in diameter (for transmural data),
whereas the original pulse sequence37 yielded a clinically
not useful performance, with a sensitivity and specificity
of 71% and 43%, respectively.29
Figure 4. Effect of different MR pulse sequences for perfusion imaging on image quality. The
spin-echo image on the left (A) represents a heart phantom containing compartments of different
concentrations of a conventional extracellular gadolinium chelate, with the highest concentration in
the core of the phantom mimicking the left ventricular blood pool and compartments of lower
concentrations mimicking normal and hypoperfused myocardium. Corresponding T1 values (in
seconds) are given in B. High image quality is obtained by use of a steady-state free precession
(ssfp) pulse sequence (acquisition window, 212 milliseconds; spatial resolution, 3  3 mm2;
non–slice-selective 90° preparation; readout flip angle, 25°; 1.5 T) (Philips Medical Systems, Best,
Netherlands) (C), which degrades steadily with increasing combined translational-rotational motion
(motion 1 and 2 in D and E, respectively). Conversely, a hybrid-EPI pulse sequence (acquisition
window, 91 milliseconds; spatial resolution, 3  3 mm2; non–slice-selective 90° preparation;
readout flip angle, 30°) shows moderate quality at rest (F), which does not deteriorate, however,
with increasing motion (G and H). This example demonstrates that pulse sequences not only differ
in the signal-CM concentration relationship but can also differ in their susceptibility for motion-
induced artifacts. Phantom measurements were performed together with Salome Ryf, PhD, Roger
Luechinger, PhD, and Sebastian Kozerke, PhD, Institute of Biomedical Engineering of the Federal
Institute of Technology, Zurich, Switzerland.
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Field Strengths
Because fast imaging is inherently coupled to a lower
SNR, a higher field strength is theoretically advantageous.
At present, very limited data on perfusion-CMR at 3 T are
available, whereas all larger studies and, in particular, all
multicenter trials are performed on 1.5-T magnets.33,34,41 In
a small study by Araoz et al42 the CNR between baseline
and peak contrast at 3 T was superior to 1.5 T. However, the
CNR at 3 T was less homogeneously distributed within the
left ventricular myocardium with a lower ratio in the
inferior wall. This part of the heart is typically exposed to
some magnetic field inhomogeneities, which appear more
relevant at 3 T.
CONTRAST MEDIA: TYPES AND DOSES
Extravascular CM
For scintigraphic techniques, there is a well-defined
relationship between tracer activity and tracer concentra-
tion (when the tracer decay time is considered), which is
one reason for PET to generate quantitative results on
perfusion and metabolism. For SPECT imaging, the
signal (ie, tracer activity) and tracer amount are linear,
though distorted to some extent by attenuation and
scatter. For CMR, the relationship between the MR
signal and the CM concentration is not linear. For
T1-enhancing CM, the signal increases with increasing
concentrations up to a maximum and declines thereafter
at higher CM concentrations.43 In addition, the shape of
this curve is dependent on the pulse sequence and
imaging parameters. For example, at lower T1-enhancing
concentrations of a conventional gadolinium chelate,
myocardial signal increases during the first pass when
acquired with a T1-weighted pulse sequence, delineating
hypoperfused myocardium as dark areas. Conversely, at
higher concentrations of the same CM, signal acquisition
with a T2-weighted pulse sequence causes a signal drop
during the first pass, delineating hypoperfused myocar-
dium as bright tissue.44 In addition, the distribution
pattern of CM within the myocardium may affect the
signal generation. Saeed et al took advantage of this
phenomenon and could demonstrate a loss of cell mem-
brane integrity using a dysprosium chelate combined
with a T2*-weighted pulse sequence.45 When concentrat-
ing on the gadolinium chelates, which are currently the
most important MR CM for clinical applications, we
have to consider their mechanism of action. Gadolinium
chelates facilitate relaxation (ie, recovery of longitudinal
magnetization) by interaction with the surrounding water
protons. This implies that, for example, gadolinium
chelates outside the cellular compartment influence the
intercellular concentration of relaxed water protons
through proton exchange over the cellular membrane.
Besides the cellular membranes, the capillary vessel wall
strongly affects the signal generation.46 Exchange con-
ditions are categorized into fast, intermediate, and slow.
Fast water exchange exists if the rate of water exchange
between compartments is considerably higher than the
difference in the longitudinal relaxation rate between the
compartments in the presence of CM, and consequently,
changes in the tissue relaxation rate reflect changes in the
blood relaxation rate.47-49 This is in contrast to the slow
intravascular-extravascular water exchange, which is the
rate-limiting step for signal generation in tissue (slow
exchange regimen).47-49 Thus neglecting water exchange
for intravascular CM can result in considerable errors in
perfusion measurements (for more details, see also ref-
erence 12). These considerations may demonstrate that
prediction of signal response during the first pass in
hyperemic tissue by mathematic models is a difficult task
and simulations will not be able to replace experiments
where true signal responses for different CM types and
doses are quantified.
The effect of increasing doses of a conventional
extracellular gadolinium chelate (Gd–diethylenetriamine
pentaacetic acid [DTPA]) on myocardial signal response
was recently evaluated in a multicenter single-vendor
study using the same hybrid-EPI pulse sequence on all
machines.33 With doses starting at 0.05 mmol/kg body
weight and increasing to 0.10 and 0.15 mmol/kg, an
increasing signal response was observed with relative
increases from baseline of approximately 100%, 200%,
and 280%, respectively. In agreement with an earlier
single-center study,29 a signal increase of about 100% in
the multicenter study yielded an unacceptable diagnostic
performance, with an area under the receiver operating
characteristic curve (AUC) of 0.51  0.13. Where high
gradients of magnetization within the imaging volume
occur, dephasing of the magnetization is increased and a
signal loss is observed. Such high gradients of magneti-
zation may build up at the blood pool–subendocardial
interface during the first pass, when CM concentrations
are high in the blood pool but are still low in the
myocardium. This situation could cause cumbersome
zones of signal loss at the subendocardial layer mimick-
ing subendocardial hypoperfusion. This type of signal
loss is called susceptibility artifact and might be propa-
gated by high CM concentrations. It was therefore
important to note that even at 0.15 mmol/kg of Gd-
DTPA combined with a hybrid-EPI acquisition, no
measurable signal loss and, consequently, no reduction
in subendocardial upslope values were observed.33 Thus
0.10 and 0.15 mmol/kg provided the advantage of a high
signal change during the first pass without causing a
measurable susceptibility artifact, resulting in an excel-
lent AUC of 0.88  0.05 for the detection of CAD
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defined as stenoses of 50% or greater in diameter on
quantitative coronary angiography. Similarly, doses from
0.01 up to 0.10 mmol/kg Gd-DTPA–bismethylamdie
(BMA) were evaluated in a multicenter, multivendor
setting.41 This study, called MR-IMPACT (Magnetic
Resonance Imaging for Myocardial Perfusion Assess-
ment in Coronary artery disease Trial), is the largest
perfusion-CMR trial performed thus far; it was per-
formed in 18 centers worldwide and yielded the best
diagnostic performance for the highest dose of 0.10
mmol/kg, with an AUC of 0.85  0.06.41 These multi-
center trials33,41 and others10 indicate that doses of
approximately 0.10 mmol/kg body weight of a gadolin-
ium chelate for first-pass perfusion studies provide ap-
propriate diagnostic performance.
Intravascular CM
These contrast media remain in the intravascular
space during the first pass. However, as pointed out
previously, they address extravascular water protons and
are therefore not “pure” intravascular contrast media. In
addition, even during brief episodes of ischemia, endo-
thelial leakage occurs,50 which “transforms” such intra-
vascular contrast media into extravascular contrast me-
dia. It is well known from experimental51 and clinical
studies52 that during vasodilation, steal phenomena can
induce ischemia; however, it might be difficult to iden-
tify these areas a priori, with the consequence that
models considering these effects are difficult to design.53
Nevertheless, T1-enhancing intravascular contrast media
such as albumin-targeted MS-32554 or polylysine gado-
linium55 have been successfully applied in animal mod-
els. Further testing in human beings is of course neces-
sary for final assessment of the potential of intravascular
CM for perfusion imaging. Intravascular superparamag-
netic iron oxide nanoparticles (ultrasmall superparamag-
netic iron oxide) in combination with a T2-weighted
turbo spin-echo sequence were also used for perfusion
studies in human beings, causing a signal drop in
normally perfused myocardium.56 However, these com-
pounds are no longer under evaluation because of CM
accumulation in the liver.
Hyperpolarized C-13 CM
At thermal equilibrium at a field strength of 1.5 T,
the MR-active nuclei (ie, water protons) are present at
only approximately 5 ppm, because of the very low
polarization level. Thus the conventional gadolinium
chelates are only acting on this low concentration of
spins, which can be doubled by increasing the field
strength to 3 T. Newer techniques now allow the polar-
ization level of specific nuclei such as liquid C-13 in
various compounds to be increased by a factor of up to
100,000 (compared with polarization of water protons at
thermal equilibrium). Techniques for hyperpolarization
are known as para-hydrogen–induced hyperpolariza-
tion57 and dynamic nuclear polarization.58 Para-hydrogen–
induced hyperpolarization uses simpler equipment and is
fast but is only applicable to smaller C-13 molecules,
whereas dynamic nuclear polarization can be applied to
all nuclei (hydrogen 1, C-13, nitrogen 15, and so on).
The polarization degree of approximately 30% translates
into a tremendous increase in signal if appropriate MR
pulse sequences are applied. Unlike gadolinium chelates,
hyperpolarized C-13 contrast media do not accelerate the
relaxation rate of water protons, but the MR signal is
directly emitted by the hyperpolarized C-13 CM. Con-
sequently, no background signal would be acquired in
perfusion studies, and most importantly, these hyperpo-
larized C-13 contrast media act as pure intravascular
contrast media, which would allow for easier quantifica-
tion of perfusion. However, because the spin population
of C-13 molecules is far away from thermal equilibrium,
longitudinal magnetization decays with specific time
constants (depending on the type of C-13 compound),
which must be taken into account, similarly to radio-
tracer decay. In addition, depolarization as a result of
repetitive radiofrequency pulsing has to be considered,
which further destroys longitudinal magnetization. Jo-
hansson et al59 showed that depolarization can be ap-
proximated by a monoexponential function and success-
fully applied this concept for cerebral perfusion
quantification. So far, these contrast media are only
applied in animal experiments,59 but preliminary results
are encouraging. An example of a cardiac perfusion
study using an intravascular C-13 compound is given in
Figure 5.
PERFUSION DATA ANALYSES
This overview on technical aspects of perfusion-
CMR together with the varieties in CM types and doses
clearly demonstrates that perfusion-CMR today is not a
single technique but is a rapidly evolving field of
research, which now enters the clinical arena. It is
therefore not surprising that this broad spectrum of
perfusion-CMR is reflected in a similarly large spectrum
of attempts to analyze the perfusion data. While the
protocol (stress-only vs stress-rest) and the best MR
pulse sequence with its optimum imaging parameters, as
well as its appropriate CM type and dose, are not yet
entirely established, the same holds for the data analyses
currently proposed. To support development in the field
of perfusion-CMR, it appears highly desirable to estab-
lish some common definitions. This would allow for
direct comparison of the results of novel approaches or
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modifications of currently available techniques reported
in different publications. For this purpose, a visual
assessment of perfusion data would not be adequate,
because the inter-reader variability for visual assessment
has been reported to be substantial, with  values as low
as 0.30.34 Therefore two categories of assessment are
proposed: (1) visual and (2) quantitative. The quantita-
tive analysis is then further categorized into (1) quanti-
fication of perfusion-related parameters and (2) absolute
quantification of perfusion (in milliliters per minute per
gram of tissue). Whereas absolute quantification of
perfusion is still challenging and not all issues are
resolved, the quantification of perfusion-related parame-
ters appears best suited to serve as an interstudy standard.
Perfusion-related parameters have been applied widely
and are, for example, the upslope of signal during
first-pass conditions,7,10,13,14,17,26,29,33 the maximum sig-
nal during the first pass,6,8,14,54,60 the time to peak, the
mean transit time,7,14,53 the area under the signal inten-
sity–time curve,61 and many others. Before an analysis
algorithm is applied, the perfusion data are typically
registered—that is, motion resulting from a drift of the
diaphragm or even from breathing is eliminated by
shifting the images in the time series, which can be
achieved by hand or by means of algorithms. With this in
mind, it is obvious that the definition of the two catego-
ries for a quantitative analysis (perfusion-related and
absolute perfusion) is not sufficient. It should be further
defined how the data were extracted from the images: (1)
manual, (2) semiautomatic (ie, some observer interfer-
Figure 5. Perfusion assessment by hyperpolarized C-13 CMR. A time series of C-13 images is
shown in A through H demonstrating the wash-in kinetics during the first pass of an intravascular
C-13 compound in a pig. Because signal obtained from the C-13 compound is linearly related to its
concentration (considering T1-relaxation and signal decay as result of pulsing), the Kety-Schmidt
model is applicable to the signal intensity–time curves (J), and myocardial perfusion is calculated
pixel-wise and represented by a color-coded perfusion map (I). This color-coded perfusion map
represents a mean myocardial blood flow at rest of 0.98 mL · min1 · g1 and is overlayed on a
conventional H-1 proton image. To obtain this type of combined image, the radiofrequency coils
must be of a send-and-transmit type at the C-13 frequency of approximately 15 MHz (at 1.5 T)
compared with approximately 60 MHz for proton imaging. (Courtesy of Stefan Petersson, PhD, and
Klaes Golman, PhD, GE Healthcare, Malmö, Sweden.)
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ence with the images), or (3) automatic (ie, no observer
interference with the images). In this context the term
semiquantitative may be misleading, because it can mean
“perfusion-related” (although the result is given in a
quantitative measure) or it can simply describe the way
data were extracted (eg, semiautomatic).
Regarding the analysis of perfusion data, many
efforts are still needed to define the most adequate
algorithms. It should be noted that for all analysis
approaches that are based on comparisons with a normal
database, such normal databases would need to be
updated when new hardware or software is installed or
imaging parameters are changed. Although this is a
handicap compared with visual reading, a quantitative
result of perfusion studies would minimize observer
variability and would allow the activity of CAD to be
objectively monitored over time.
Perfusion data analysis cannot be addressed without
covering the issue of data quality. There is clearly a
reciprocal relationship for a given analysis algorithm
between its “automaticity” and its diagnostic perfor-
mance. In other words, a fully automatic algorithm
applied to high-quality data is likely to perform well
(minimum number of nonevaluable studies and high
AUC compared with a standard of reference), with
virtually absent observer variability. On the other hand,
with low-quality data, a high number of failures will be
produced, and a manual analysis would perform better
but at the cost of observer dependence in the latter case.
Accordingly, it will be a major task in the future to
establish criteria or, even better, computerized algo-
rithms that would define data quality. Categories of
qualities would then be available qualifying a given data
set for a particular analysis algorithm for which the
diagnostic performance is known. In a single-vendor
multicenter trial, for example, the diagnostic perfor-
mance of perfusion-CMR with an AUC of 0.72 (at 0.1
mmol/kg Gd-DTPA) for CAD detection was increased to
0.91 when eliminating 14% of all studies that were of
low quality and including only the central 3 (high-
quality) slices in the analysis algorithm.33 Such standard-
izations are deemed crucial if the impact of perfusion-
CMR in cardiology should increase and estimations of
cost-effectiveness should become available.
VIABILITY AND METABOLIC IMAGING BY CMR
Monitoring CAD activity by perfusion-CMR would
detect ischemia and thus the patient at risk in an early
stage. This would allow for interventions and conse-
quently the avoidance of infarctions in the ideal case.
Unfortunately, this ideal situation is still far away.
Instead, the number of patients with a mixture of chronic
infarctions and ischemia is increasing. Accordingly, a
complete workup of CAD patients clearly requires de-
tection of hypoperfusion (during hyperemia) and its
characterization as being either present in viable tissue
(ie, ischemic tissue during conditions of increased oxy-
gen demand or hibernating tissue with reduced function
at rest) or present in nonviable tissue (ie, scar tissue).
Therefore perfusion-CMR should be followed by viabil-
ity imaging when hypoperfused areas are detected, par-
ticularly if these hypoperfused areas show reduced func-
tion at rest. As shown in Figure 1, CMR probes the
distribution volume of conventional gadolinium chelates
during steady-state conditions, which occur approxi-
mately 15 to 20 minutes after injection of 0.15 to 0.25
mmol/kg intravenously.62 Stressing the need to wait for
this steady-state condition to occur, the CMR technique
is called either an LE- or DE-CMR technique. This
technique is less demanding with respect to the gradient
system of the scanner, because the time window for
imaging lasts several minutes (compared with 1-2 RR
intervals for perfusion-CMR), which allows coverage of
the entire heart with a spatial resolution on the order of
1 to 2 mm  1 to 2 mm. This high spatial resolution
discriminates small subendocardial scar regions,63 which
are not detectable by PET62,64 or SPECT65 on a regular
basis. This detailed insight into the transmural scar
distribution was analyzed to predict functional recovery
in patients after revascularization.62 It was demonstrated
that both conditions must be met for functional recovery—
that is, sufficient viable rim tissue (approximately4.5 mm
rim thickness) and no or small scar tissue (approximately
4 mm). This study also showed that mismatch seg-
ments on FDG-PET imaging were most prevalent in
segments with a substantial rim of viable tissue on
LE-CMR, indicating that mismatch segments are prefer-
entially encountered in the subepicardial layer of scar
regions. Thus CMR and PET can provide complemen-
tary information, but CMR may add metabolic informa-
tion to functional, perfusion, and viability information as
well. Although MR spectroscopy of the heart66 and
skeletal muscle67 is feasible to quantify high-energy
phosphates, it may not access all parts of the heart with
high resolution. Here, hyperpolarized C-13 CM may
open a new chapter in metabolic imaging.
Hyperpolarized C-13 CM
Whereas some hyperpolarized C-13 compounds re-
main intravascular and can be used for perfusion quan-
tification (Figure 5), other hyperpolarized C-13 com-
pounds may act to trace the citric acid cycle to determine
the oxygen consumption of the cell, to measure the pH,
or to trace other metabolites within the cells. Given the
high signal available, this metabolic information can be
obtained with millimeter resolution updated every few
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seconds (ie, in near real time). Moreover, in the same
voxel spectra can be acquired that allow for identification
and quantification of several different compounds simul-
taneously by use of chemical shift imaging or even faster
approaches such as multiecho steady-state free preces-
sion pulse sequences.23 Because the resonance frequency
of the metabolic products of, for example, C-13-pyruvate
is sufficiently separated from the frequency of C-13-
pyruvate itself, it is possible to trace the C-13 atom
through the various metabolic and catabolic pathways in
the cells in vivo.23 This is different from PET imaging,
which visualizes the active nuclei irrespective of whether
they are still contained in the injected tracer. Thus
monitoring the fate of C-13-pyruvate into its metabolites,
C-13-alanine and C-13-lactate, is possible in near–real-
time imaging, whereas the tissue concentration of C1-
pyruvate is a measure of tissue perfusion. In addition, a
low concentration of HCO3 is indicative of a low
regional tissue pH (pH-dependent CO2↔HCO3 equi-
librium). Whereas hibernation might represent a mecha-
nism to downregulate function to preserve tissue struc-
ture and cell homeostasis, it was hypothesized that after
an ischemic insult, cellular metabolism might change
toward anaerobic energy production to preserve cell
function. If this is true and changes would persist, this
adaptive change of metabolism would represent a kind of
metabolic memory. The presence of metabolic memory
is demonstrated by use of C-13 metabolic CMR imaging
in Figure 6, where metabolic alteration of the citric acid
(Krebs) cycle was demonstrated 2 hours after a short
ischemic insult of 15 minutes’ duration.
FUTURE PERSPECTIVES OF PERFUSION-CMR
In the past few years considerable improvements
were achieved in the treatment of CAD, particularly
with the invention of drug-eluting stents, which re-
duced the rate of in-stent restenoses considerably.
Figure 6. Metabolic assessment by hyperpolarized C-13 CMR. In this pig experiment hyperpolar-
ized C-13-pyruvate was injected intravenously at baseline, and chemical shift imaging was used to
monitor the metabolism of C-13-pyruvate into C-13-lactate, C-13-alanine, and bicarbonate, as
shown in the upper row (A-D). Conventional proton imaging for assessment of contractile function
and LE imaging for assessment of viability were also performed. After baseline imaging, the animal
was subjected to 15 minutes of left circumflex coronary artery occlusion by an inflated balloon
catheter. After 2 hours of reperfusion, it was again studied by C-13 chemical shift imaging after
injection of hyperpolarized C-13-pyruvate (lower row [E-H]). Although hyperpolarized C-13-
pyruvate is represented in all myocardial segments both at baseline (A) and after the ischemic insult
(E), metabolic imaging demonstrates a severe reduction in bicarbonate in the formerly ischemic
territory of the lateral wall (G) whereas C-13-lactate content is increased in the same territory (F),
without a notable change in C-13-alanine (H). This change in the metabolism of C-13-pyruvate (ie,
the Krebs cycle) is detected 2 hours after a relatively short ischemic period of only 15 minutes,
demonstrating the phenomenon of metabolic memory. (Courtesy of Stefan Petersson, PhD, and
Klaes Golman, PhD, GE Healthcare, Malmö, Sweden.)
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This, in combination with percutaneous coronary in-
terventions performed in the setting of acute coronary
syndromes, changed the outcome of these high-risk
patients. Nevertheless, about 40% of patients having
an acute coronary attack die from it, most of them in
the preclinical phase or in the emergency department
before undergoing a rescue percutaneous coronary
intervention,68 indicating that the identification of
high-risk patients with currently established guide-
lines is not optimal. The increasing number of SPECT
studies in the past years demonstrates the need for a
noninvasive approach to identify the patients at risk,
with approximately half of them being asymptomatic
before cardiac death.68 Therefore a shift is likely to
occur from a “reactive” strategy, where patients with
symptoms predominantly undergo further diagnostic
workup, to an “active” strategy, where patients will
undergo additional noninvasive investigations accord-
ing to their risk profile. For such an “active” strategy,
perfusion-CMR would be ideally suited, because large
multicenter studies have demonstrated a good diag-
nostic performance of the technique.33,41 It is repeat-
able and safe, and costs are expected to be similar to
costs of other noninvasive techniques. Substantial data
are available for SPECT demonstrating its cost-effec-
tiveness,5 and it is hoped that such data will soon be
available for the CMR technique as well. As pointed
out previously, considerable efforts will be needed in
the near future to standardize the perfusion-CMR
protocols, the pulse sequences, and the analysis meth-
ods. In a next step the performance of the various
diagnostic techniques should be compared in prospec-
tive trials to identify the best indications for each
technique. For the successful conduction of future
comparative studies, close cooperation between the
representatives of the various techniques in noninva-
sive cardiology will be crucial.69 It will then be an
ongoing challenge to adapt the established guidelines
for diagnostic workup.
Of course, for an “active” strategy, the following
question has to be addressed: At which level of risk
should an individual patient undergo a diagnostic
workup?70 In addition to the classical cardiovascular
risk factors, the risk of an individual patient could be
further characterized by plaque imaging, by probing
the endothelial function (eg, by sophisticated MR
techniques),71 by hyperpolarized C-13 CM metabolic
imaging, or by screening the genome.72 (However, the
number of candidate genes associated with cardiovas-
cular diseases is extremely high, making a distinction
between random and true biologic associations diffi-
cult.) A combination of these various aspects of
vascular disease will be most promising in identifying
the patients who will benefit most from early risk
management and a monitoring strategy of CAD activ-
ity to determine the optimum time point for coronary
interventions before infarctions occur.
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